Investment
Features
FeesSafety
Academy
More
Pluang+

Compare NetFlix Inc (NFLX) vs Novavax Inc (NVAX) Price & Performance

NetFlix IncTrade
Novavax IncTrade

Price performance (Past 24H)

Key statistics

NetFlix Inc vs Novavax Inc — how do they compare? NetFlix Inc trades at $68.23 (market cap $281.48B), while Novavax Inc trades at $8.08 (market cap $1.30B). The key difference: NetFlix Inc is far larger — about 216.5× Novavax Inc's market cap, and Novavax Inc is trading nearer its 52-week high, NetFlix Inc nearer its low. Which is the better fit depends on your goals.

NFLXNVAX
Market Cap
$281.48B$1.30B
Sector
Consumer CyclicalHealth
52-Week High
$126.33$11.19
52-Week Low
$67.60$6.22
Enterprise Value
$286.66B$800.50M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

NetFlix Inc

Netflix (NFLX) is trading at $68.95, down 7.26% over 24 hours and approaching its 52-week low. The stock shows bearish technical signals with oversold RSI levels, while fundamentals remain strong with Q1 2026 EPS beating expectations at $1.23 versus $0.763. Revenue grew to $45.18B in 2025 with a net income margin of 24.3%, though valuation ratios like P/E of 21.26 and P/S of 6.02 suggest moderate pricing. Recent news highlights stock declines despite business growth, with focus on advertising expansion and content performance.

The outlook for NFLX is mixed; strong earnings and ad-tier scalability offer upside, but technical weakness and competitive pressures pose risks. Analysts maintain a buy consensus with a $90.47 price target, implying significant potential appreciation. Key risks include market sentiment shifts and execution challenges in new revenue streams, requiring careful monitoring of quarterly results and subscriber trends.

Novavax Inc

Novavax (NVAX) trades at $8.08, down 1.64% on the day, with a bearish technical signal but strong recent earnings beats. The company reported $1.12B revenue in 2025 with a net income of $440.30M, though 2026 projections show a return to losses. Analyst consensus is bullish with a $14.00 price target, but negative shareholder equity and cash flow concerns persist.

Outlook remains mixed: strong valuation ratios and analyst support suggest upside potential, but negative cash flows, high liabilities, and projected 2026 losses pose significant risks. Investor sentiment is cautious amid recent stock declines and shareholder dissent highlighted in recent news.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About NetFlix Inc

Netflix Inc. is an Internet subscription service for watching television shows and movies. Subscribers can instantly watch unlimited television shows and movies streamed over the Internet to their televisions, computers, and mobile devices and in the United States, subscribers can receive standard definition DVDs and Blu-ray Discs delivered to their homes.

Read more on NFLX

About Novavax Inc

Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.

Read more on NVAX